Early diagnosis of skin cancers has never been that easy !
ONCOMECA is a Class IIb medical device according to european regulation 2017/745. Our technology lies in the early identification of skin cancers. Our expertise has been miniaturized and automated to provide 90% easy-to-use and reliable technology!
“At ONCOMECA, we innovate to provide early diagnosis for all.”
Julien Chlasta CEO, ONCOMECA
Today…
First-line patients consult their GP. When a lesion appears suspicious, they are referred to a dermatologist.
Dermatologists use a small tool, a dermoscope, to diagnose skin lesions.
- Visual Rule Detection (ABCDE)
- Early stages are visually difficult to detect
- High level of expertise
When the dermatologist suspects melanoma, surgery is quickly scheduled to remove the tumor and perform biopsies. A large excision, including healthy tissue, is then performed. Depending on the size of the excision, a skin graft may be required. Tissues and biopsies are then analyzed by the pathologist who confirms or not the suspicion and cancer spread. The diagnosis is then made. At this point, this spread has often begun. Chemotherapy or radiation therapy may then be necessary to treat the patient.
Tomorrow…
ONCOMECA will be made available to doctors free of charge:
- Easy to use
- Non-invasive and painless
- Real-time diagnosis
- Reliability above 90%
- Detect very early stages
- The diagnosis will be made as soon as the medical visit
Excision to remove the tumour will then be reduced. Biopsies will also be performed. Tissues and biopsies will then be analyzed by the pathologist who will confirm or not the initial diagnosis and the cancer spread. At these early stages, the cancer is unlikely to have spread. Chemo and radiotherapy treatments may be limited or unnecessary. The patient can therefore simply be followed by his general practitioner or dermatologist.
skin cancers occurring each year in the world
cancers diagnosed is a skin cancer
%
reliable technology
Patent & Licence with a unique know-how
- Early and easy diagnosis will be available soon!
- At ONCOMECA, our innovation is both patient and physician oriented.
- Our goal is to provide a high quality medical device.
- With this in mind, our team focuses on our quality system to be ISO 13485 certified.
“The mechanical properties reflect the histological progression in principle, so if it is validated, the device offers a way to evaluate it. Why not, it sounds practical.”
“Simple, practical, useful, should be part of our daily practice, such as measuring blood pressure.”
“A step towards the prevention of serious cancer with a high mortality rate. A 15 x 3cm device, quite user-friendly, which allows us to intervene significantly in the decision tree instead of wasting our time trying to contact a dermatologist, to contact the secretary, etc. This will certainly help us save time.”
The Team
Julien CHLASTA
Co-Founder & CEO
Research and Development
Industrialization
Yannis ROBIN-LESPINASSE
Co-Founder & COO
Chief Operating Officer
Market
Financing
Hélène CHAUSSARD
Quality/Regulatory Affairs Director
Setting up
ISO 13485: 2016
CE Marking
Thibault Singland
Communication Manager
Setting up
Content
– Scientific Committee: 3 people / Scientists and Doctors of international renown
– Strategic Committee: 3 people / 1 Executive of an Grand International Pharmaceutical Group
– BIOMECA SAS support functions
Partners
